DURECT Corporation Logo

DURECT Corporation

DRRX

(0.5)
Stock Price

0,95 USD

-66.7% ROA

-232.73% ROE

-2.55x PER

Market Cap.

40.351.220,00 USD

318.92% DER

0% Yield

-198.62% NPM

DURECT Corporation Stock Analysis

DURECT Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

DURECT Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (2.73x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

3 ROE

Negative ROE (-176.78%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-83.92%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The stock is burdened with a heavy load of debt (415%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

DURECT Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

DURECT Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

DURECT Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

DURECT Corporation Revenue
Year Revenue Growth
1999 86.000
2000 3.155.000 97.27%
2001 6.524.000 51.64%
2002 7.185.000 9.2%
2003 11.835.000 39.29%
2004 13.853.000 14.57%
2005 28.571.000 51.51%
2006 21.894.000 -30.5%
2007 30.675.000 28.63%
2008 25.957.000 -18.18%
2009 24.293.000 -6.85%
2010 31.591.000 23.1%
2011 33.487.000 5.66%
2012 53.070.000 36.9%
2013 15.326.000 -246.27%
2014 19.401.000 21%
2015 19.124.000 -1.45%
2016 14.025.000 -36.36%
2017 49.170.000 71.48%
2018 18.564.000 -164.87%
2019 29.564.000 37.21%
2020 30.111.000 1.82%
2021 13.977.000 -115.43%
2022 19.283.000 27.52%
2023 6.976.000 -176.42%
2023 8.548.000 18.39%
2024 8.684.000 1.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

DURECT Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1999 6.363.000
2000 13.335.000 52.28%
2001 24.570.000 45.73%
2002 29.554.000 16.86%
2003 20.948.000 -41.08%
2004 24.233.000 13.56%
2005 28.904.000 16.16%
2006 37.241.000 22.39%
2007 38.342.000 2.87%
2008 39.411.000 2.71%
2009 34.913.000 -12.88%
2010 36.214.000 3.59%
2011 34.053.000 -6.35%
2012 20.265.000 -68.04%
2013 18.945.000 -6.97%
2014 22.429.000 15.53%
2015 24.317.000 7.76%
2016 29.274.000 16.93%
2017 31.609.000 7.39%
2018 25.501.000 -23.95%
2019 30.209.000 15.58%
2020 27.709.000 -9.02%
2021 31.846.000 12.99%
2022 36.862.000 13.61%
2023 28.796.000 -28.01%
2023 29.351.000 1.89%
2024 8.988.000 -226.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

DURECT Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 12.174.000 100%
2003 8.396.000 -45%
2004 9.951.000 15.63%
2005 11.271.000 11.71%
2006 12.417.000 9.23%
2007 13.618.000 8.82%
2008 15.462.000 11.93%
2009 15.020.000 -2.94%
2010 14.937.000 -0.56%
2011 13.574.000 -10.04%
2012 12.095.000 -12.23%
2013 12.706.000 4.81%
2014 12.284.000 -3.44%
2015 11.566.000 -6.21%
2016 11.825.000 2.19%
2017 13.165.000 10.18%
2018 12.419.000 -6.01%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

DURECT Corporation EBITDA
Year EBITDA Growth
1999 -9.048.000
2000 -21.323.000 57.57%
2001 -18.044.000 -18.17%
2002 -34.650.000 47.92%
2003 -16.534.000 -109.57%
2004 -19.669.000 15.94%
2005 -12.056.000 -63.15%
2006 -26.686.000 54.82%
2007 -21.505.000 -24.09%
2008 -45.761.000 53.01%
2009 -31.519.000 -45.19%
2010 -23.835.000 -32.24%
2011 -18.853.000 -26.43%
2012 17.171.000 209.8%
2013 -21.162.000 181.14%
2014 -20.959.000 -0.97%
2015 -20.427.000 -2.6%
2016 -32.221.000 36.6%
2017 -1.270.000 -2437.09%
2018 -22.749.000 94.42%
2019 -18.077.000 -25.84%
2020 -12.098.000 -49.42%
2021 -34.117.000 64.54%
2022 -32.934.000 -3.59%
2023 -35.616.000 7.53%
2023 -36.736.000 3.05%
2024 -13.624.000 -169.64%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

DURECT Corporation Gross Profit
Year Gross Profit Growth
1999 358.000
2000 1.864.000 80.79%
2001 3.126.000 40.37%
2002 4.099.000 23.74%
2003 9.408.000 56.43%
2004 11.124.000 15.43%
2005 25.756.000 56.81%
2006 18.646.000 -38.13%
2007 27.450.000 32.07%
2008 22.592.000 -21.5%
2009 18.950.000 -19.22%
2010 27.316.000 30.63%
2011 28.774.000 5.07%
2012 48.416.000 40.57%
2013 10.489.000 -361.59%
2014 13.715.000 23.52%
2015 15.219.000 9.88%
2016 8.735.000 -74.23%
2017 42.537.000 79.46%
2018 14.301.000 -197.44%
2019 25.421.000 43.74%
2020 28.705.000 11.44%
2021 12.022.000 -138.77%
2022 17.695.000 32.06%
2023 5.728.000 -208.92%
2023 6.831.000 16.15%
2024 7.260.000 5.91%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

DURECT Corporation Net Profit
Year Net Profit Growth
1999 -8.708.000
2000 -19.851.000 56.13%
2001 -44.928.000 55.82%
2002 -37.173.000 -20.86%
2003 -22.698.000 -63.77%
2004 -27.637.000 17.87%
2005 -18.128.000 -52.45%
2006 -33.327.000 45.61%
2007 -24.339.000 -36.93%
2008 -45.051.000 45.97%
2009 -30.715.000 -46.67%
2010 -22.898.000 -34.14%
2011 -18.765.000 -22.03%
2012 16.200.000 215.83%
2013 -21.452.000 175.52%
2014 -22.110.000 2.98%
2015 -22.663.000 2.44%
2016 -34.509.000 34.33%
2017 -3.695.000 -833.94%
2018 -25.322.000 85.41%
2019 -22.788.000 -11.12%
2020 -2.522.000 -803.57%
2021 -38.125.000 93.38%
2022 -35.584.000 -7.14%
2023 -12.060.000 -195.06%
2023 -27.624.000 56.34%
2024 -14.800.000 -86.65%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

DURECT Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 -4
2000 -12 72.73%
2001 -10 -22.22%
2002 -8 -28.57%
2003 -4 -75%
2004 -5 20%
2005 -3 -66.67%
2006 -5 40%
2007 -3 -66.67%
2008 -6 40%
2009 -4 -66.67%
2010 -3 -50%
2011 -2 0%
2012 2 300%
2013 -2 150%
2014 -2 0%
2015 -2 -100%
2016 -3 50%
2017 0 0%
2018 -2 100%
2019 -1 0%
2020 0 0%
2021 -2 100%
2022 -2 0%
2023 0 0%
2023 -1 100%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

DURECT Corporation Free Cashflow
Year Free Cashflow Growth
1999 -8.287.000
2000 -18.688.000 55.66%
2001 -29.786.000 37.26%
2002 -32.720.000 8.97%
2003 -20.207.000 -61.92%
2004 -23.346.000 13.45%
2005 -9.608.000 -142.99%
2006 -11.699.000 17.87%
2007 -20.940.000 44.13%
2008 -10.356.000 -102.2%
2009 -21.188.000 51.12%
2010 7.507.000 382.24%
2011 -19.853.000 137.81%
2012 -13.738.000 -44.51%
2013 -15.517.000 11.46%
2014 -14.413.000 -7.66%
2015 -20.780.000 30.64%
2016 -27.440.000 24.27%
2017 -1.412.000 -1843.34%
2018 -19.843.000 92.88%
2019 10.946.000 281.28%
2020 -38.912.000 128.13%
2021 -37.505.000 -3.75%
2022 -26.391.000 -42.11%
2023 -34.466.000 23.43%
2023 -7.496.000 -359.79%
2024 -3.666.000 -104.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

DURECT Corporation Operating Cashflow
Year Operating Cashflow Growth
1999 -7.271.000
2000 -14.887.000 51.16%
2001 -22.428.000 33.62%
2002 -31.307.000 28.36%
2003 -19.246.000 -62.67%
2004 -22.208.000 13.34%
2005 -7.211.000 -207.97%
2006 -9.479.000 23.93%
2007 -18.295.000 48.19%
2008 -9.434.000 -93.93%
2009 -20.894.000 54.85%
2010 7.763.000 369.15%
2011 -17.386.000 144.65%
2012 -13.448.000 -29.28%
2013 -15.448.000 12.95%
2014 -14.209.000 -8.72%
2015 -20.555.000 30.87%
2016 -27.293.000 24.69%
2017 -1.343.000 -1932.24%
2018 -19.750.000 93.2%
2019 11.101.000 277.91%
2020 -38.704.000 128.68%
2021 -37.311.000 -3.73%
2022 -26.280.000 -41.97%
2023 -34.414.000 23.64%
2023 -7.483.000 -359.9%
2024 -3.666.000 -104.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

DURECT Corporation Capital Expenditure
Year Capital Expenditure Growth
1999 1.016.000
2000 3.801.000 73.27%
2001 7.358.000 48.34%
2002 1.413.000 -420.74%
2003 961.000 -47.03%
2004 1.138.000 15.55%
2005 2.397.000 52.52%
2006 2.220.000 -7.97%
2007 2.645.000 16.07%
2008 922.000 -186.88%
2009 294.000 -213.61%
2010 256.000 -14.84%
2011 2.467.000 89.62%
2012 290.000 -750.69%
2013 69.000 -320.29%
2014 204.000 66.18%
2015 225.000 9.33%
2016 147.000 -53.06%
2017 69.000 -113.04%
2018 93.000 25.81%
2019 155.000 40%
2020 208.000 25.48%
2021 194.000 -7.22%
2022 111.000 -74.77%
2023 52.000 -113.46%
2023 13.000 -300%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

DURECT Corporation Equity
Year Equity Growth
1999 20.728.000
2000 115.254.000 82.02%
2001 97.048.000 -18.76%
2002 66.182.000 -46.64%
2003 45.115.000 -46.7%
2004 18.390.000 -145.32%
2005 43.352.000 57.58%
2006 37.032.000 -17.07%
2007 34.581.000 -7.09%
2008 36.419.000 5.05%
2009 27.416.000 -32.84%
2010 14.487.000 -89.25%
2011 3.477.000 -316.65%
2012 36.331.000 90.43%
2013 30.721.000 -18.26%
2014 18.515.000 -65.92%
2015 14.883.000 -24.4%
2016 8.338.000 -78.5%
2017 21.488.000 61.2%
2018 20.000.000 -7.44%
2019 22.860.000 12.51%
2020 40.115.000 43.01%
2021 57.782.000 30.58%
2022 24.985.000 -131.27%
2023 14.406.000 -73.43%
2023 14.783.000 2.55%
2024 5.037.000 -193.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

DURECT Corporation Assets
Year Assets Growth
1999 22.463.000
2000 120.612.000 81.38%
2001 104.943.000 -14.93%
2002 72.971.000 -43.81%
2003 112.407.000 35.08%
2004 85.468.000 -31.52%
2005 117.414.000 27.21%
2006 102.485.000 -14.57%
2007 84.020.000 -21.98%
2008 74.874.000 -12.22%
2009 58.151.000 -28.76%
2010 67.560.000 13.93%
2011 49.196.000 -37.33%
2012 45.935.000 -7.1%
2013 40.820.000 -12.53%
2014 50.084.000 18.5%
2015 46.772.000 -7.08%
2016 40.508.000 -15.46%
2017 53.113.000 23.73%
2018 49.999.000 -6.23%
2019 86.020.000 41.88%
2020 75.641.000 -13.72%
2021 91.990.000 17.77%
2022 60.100.000 -53.06%
2023 54.728.000 -9.82%
2023 45.189.000 -21.11%
2024 29.854.000 -51.37%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

DURECT Corporation Liabilities
Year Liabilities Growth
1999 1.735.000
2000 5.358.000 67.62%
2001 7.895.000 32.13%
2002 6.789.000 -16.29%
2003 67.292.000 89.91%
2004 67.078.000 -0.32%
2005 74.062.000 9.43%
2006 65.453.000 -13.15%
2007 49.439.000 -32.39%
2008 38.455.000 -28.56%
2009 30.735.000 -25.12%
2010 53.073.000 42.09%
2011 45.719.000 -16.09%
2012 9.604.000 -376.04%
2013 10.099.000 4.9%
2014 31.569.000 68.01%
2015 31.889.000 1%
2016 32.170.000 0.87%
2017 31.625.000 -1.72%
2018 29.999.000 -5.42%
2019 63.160.000 52.5%
2020 35.526.000 -77.79%
2021 34.208.000 -3.85%
2022 35.115.000 2.58%
2023 40.322.000 12.91%
2023 30.406.000 -32.61%
2024 24.817.000 -22.52%

DURECT Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.27
Net Income per Share
-0.51
Price to Earning Ratio
-2.55x
Price To Sales Ratio
4.8x
POCF Ratio
-1.54
PFCF Ratio
-1.6
Price to Book Ratio
8.01
EV to Sales
4.85
EV Over EBITDA
-1.67
EV to Operating CashFlow
-1.55
EV to FreeCashFlow
-1.62
Earnings Yield
-0.39
FreeCashFlow Yield
-0.62
Market Cap
0,04 Bil.
Enterprise Value
0,04 Bil.
Graham Number
1.36
Graham NetNet
-0.23

Income Statement Metrics

Net Income per Share
-0.51
Income Quality
1.66
ROE
-1.49
Return On Assets
-0.71
Return On Capital Employed
-5.01
Net Income per EBT
1
EBT Per Ebit
0.88
Ebit per Revenue
-2.25
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
2.28
Stock Based Compensation to Revenue
0.26
Gross Profit Margin
0.79
Operating Profit Margin
-2.25
Pretax Profit Margin
-1.99
Net Profit Margin
-1.99

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.85
Free CashFlow per Share
-0.81
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.12
Capex to Depreciation
510.5
Return on Invested Capital
-1.15
Return on Tangible Assets
-0.67
Days Sales Outstanding
43.92
Days Payables Outstanding
89.05
Days of Inventory on Hand
559.14
Receivables Turnover
8.31
Payables Turnover
4.1
Inventory Turnover
0.65
Capex per Share
0.03

Balance Sheet

Cash per Share
0,50
Book Value per Share
0,16
Tangible Book Value per Share
-0.04
Shareholders Equity per Share
0.16
Interest Debt per Share
0.59
Debt to Equity
3.19
Debt to Assets
0.54
Net Debt to EBITDA
-0.02
Current Ratio
0.91
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
7648000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.21
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2436000
Debt to Market Cap
0.4

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

DURECT Corporation Dividends
Year Dividends Growth

DURECT Corporation Profile

About DURECT Corporation

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

CEO
Dr. James E. Brown D.V.M.
Employee
48
Address
10260 Bubb Road
Cupertino, 95014-4166

DURECT Corporation Executives & BODs

DURECT Corporation Executives & BODs
# Name Age
1 Dr. James E. Brown D.V.M.
Co-Founder, Chief Executive Officer, President & Director
70
2 Mr. Timothy M. Papp M.B.A.
Chief Financial Officer & Secretary
70
3 Dr. Norman L. Sussman M.D.
Chief Medical Officer
70
4 Ms. Jian Li M.B.A.
Senior Vice President of Finance, Corporate Controller & Secretary
70
5 Ms. Judy R. Joice
Senior Vice President of Operations & Corporate Quality Assurance
70
6 Dr. Su Il Yum Ph.D.
Executive Officer
70
7 Dr. WeiQi Lin M.D., Ph.D.
Executive Vice President of Research & Development and Principal Scientist
70

DURECT Corporation Competitors